Asbestos Research Today is a free monthly online journal that collates and summarizes the latest research about Asbestos, including details on mesothelioma, lung disease, dangers, effects, risks.

Volume 4 (2007), Issue 9 (September)

1. Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers.
   Clin Cancer Res, 13(17): 5144-9. [Abstract] [Full-text]
2. Clinical significance of serum mesothelin in patients with mesothelioma and lung cancer.
   Clin Cancer Res, 13(17): 5076-81. [Abstract] [Full-text]
3. Ras pathway activation in malignant mesothelioma.
   J Thorac Oncol, 2(9): 789-95. [Abstract] [Full-text]
4. Low-molecular weight forms of cyclin E differentiate ovarian carcinoma from cells of mesothelial origin and are associated with poor survival in ovarian carcinoma.
   Cancer, 110(6): 1264-71. [Abstract] [Full-text]
5. Assessment of tumor response in malignant pleural mesothelioma.
   Cancer Treat Rev, 33(6): 533-41. [Abstract] [Full-text]
6. Dose-dependent pulmonary toxicity after postoperative intensity-modulated radiotherapy for malignant pleural mesothelioma.
   Int J Radiat Oncol Biol Phys, 69(2): 350-7. [Abstract] [Full-text]

© 2004-2008 Asbestos Research Today. All Rights Reserved.